[
    [
        {
            "time": "2018-01-02",
            "original_text": "Benzinga's Weekly Bulls & Bears: AbbVie, Kinder Morgan, Paypay, Starbucks, Wynn And More",
            "features": {
                "keywords": [
                    "Bulls",
                    "Bears",
                    "AbbVie",
                    "Kinder Morgan",
                    "Paypal",
                    "Starbucks",
                    "Wynn"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "energy",
                    "technology",
                    "consumer goods",
                    "hospitality"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Benzinga's Weekly Bulls & Bears: AbbVie, Kinder Morgan, Paypay, Starbucks, Wynn And More",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "What to Expect With Gilead Sciences' Q4 Results",
            "features": {
                "keywords": [
                    "Gilead",
                    "Q4",
                    "Results"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "What to Expect With Gilead Sciences' Q4 Results",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "3 Headwinds in Q4 Earnings Results That Make Merck a Mediocre Stock",
            "features": {
                "keywords": [
                    "Headwinds",
                    "Q4",
                    "Earnings",
                    "Merck"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "3 Headwinds in Q4 Earnings Results That Make Merck a Mediocre Stock",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "What to Expect With Gilead Sciences' Q4 Results",
            "features": {
                "keywords": [
                    "Gilead",
                    "Q4",
                    "Results"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "What to Expect With Gilead Sciences' Q4 Results",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]